SecBot SecBot
8-K ·Filed Feb 24, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed8mo ago SEC0001193125-26-067546
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor future 8-K filings for announcements of actual sales under this ATM program, which will disclose the number of shares sold, sale price, and net proceeds. The timing and volume of any sales will signal management's view on the current stock valuation and funding needs.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$63.04
T+0 close · Feb 24, 2026 · via day close
Latest settled
−25.17%
T+60 · $47.17
Vs SPY
−32.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $63.04entry
  2. T+1 · 9mo ago −4.82%α −4.28% · $60.00
  3. T+5 · 9mo ago −4.62%α −3.52% · $60.13
  4. T+20 · 8mo ago −11.31%α −6.07% · $55.91
  5. T+60 · 6mo ago −25.17%α −32.13% · $47.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxcyte entered into an at-the-market (ATM) sales agreement with Leerink Partners LLC to sell up to $500 million in common stock. The company also terminated its prior ATM agreement with Jefferies LLC, under which it had raised approximately $270.3 million. This new facility provides Vaxcyte with ongoing access to capital markets, subject to market conditions and its discretion on timing and size of offerings.

Key Facts

  • Vaxcyte entered into a new sales agreement with Leerink Partners LLC for an at-the-market equity offering program.
  • The maximum aggregate offering amount under the new agreement is $500,000,000.
  • The shares are registered under an existing shelf registration statement (Form S-3) that became effective on May 24, 2024.
  • Leerink Partners will act as sales agent and receive a commission of up to 3.00% of the gross proceeds.
  • Vaxcyte is not obligated to sell any shares, and Leerink is not obligated to buy or sell any shares.
  • The company terminated its prior Open Market Sale Agreement with Jefferies LLC, under which it had sold shares with an aggregate offering price of approximately $270.3 million.

Financial Impact

Up to $500 million in potential gross proceeds, with a 3% agent commission. No immediate financial impact as sales are discretionary and will occur over time.

dilutionequity

Risk Factors

  • Equity dilution for existing shareholders if shares are sold.
  • Potential downward pressure on the stock price if sales occur during periods of weak market conditions or low trading volume.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-067546
Document: d259722d8k.htm0001193125-26-067546
Document: d259722dex51.htm0001193125-26-067546
Document: 0001193125-26-067546-index-headers.html0001193125-26-067546
Document: 0001193125-26-067546-index.html0001193125-26-067546
Document: 0001193125-26-067546.txt0001193125-26-067546

US Market Status

Market Closed · Opens Wed (11h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 24, 2026